Literature DB >> 11352522

Long-term follow-up of percutaneous vena cava filters: a prospective study in 100 consecutive patients.

J M Schleich1, O Morla, M Laurent, B Langella, J Chaperon, C Almange.   

Abstract

OBJECTIVES: the long-term outcome in following insertion of inferior vena cava (IVC) filters remains unclear.
DESIGN: prospective study.
MATERIAL AND METHODS: one hundred consecutive patients received percutaneous vena cava filters between 1988 and 1993. The patients underwent clinical examination, abdominal X-rays and duplex ultrasound of the IVC, right internal jugular vein and legs after a mean follow-up duration of 38+/-11 months.
RESULTS: forty patients died after implantation (median 11.3 months; IQR: 1.8--20.4 months). The cause of death was known in 33 cases, and pulmonary embolism (PE) was suggested in three. Multivariate analysis revealed the mortality rate to be significantly higher in cancer patients (relative risk of 2.13). The 3-year survival was 20% for cancer patients and 71% for patients without cancer. Among the 60 living patients, thrombi were trapped in the filter in 10 cases, the filter tilted in four, was malpositioned in five and migrated in 29. These incidents were recorded as asymptomatic complications, as opposed to seven IVC thromboses and 23 recurrent lower limb thromboses, which were considered as symptomatic complications.
CONCLUSION: long-term major complications are not frequent. As expected, cancer was the only factor predicting mortality. IVC filters seem effective in preventing PE. Copyright 2001 Harcourt Publishers Limited.

Entities:  

Mesh:

Year:  2001        PMID: 11352522     DOI: 10.1053/ejvs.2001.1319

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  5 in total

1.  Fatal migration of vena caval filters.

Authors:  Zoya Shmuter; Frede I Frederic; James R Gill
Journal:  Forensic Sci Med Pathol       Date:  2007-09-11       Impact factor: 2.007

2.  The mid-term efficacy and safety of a permanent nitinol IVC filter(TrapEase).

Authors:  Wei Chiang Liu; Young Soo Do; Sung Wook Choo; Dong-Ik Kim; Young Wook Kim; Duk-Kyung Kim; Sung Wook Shin; Kwang Bo Park; Yong Hwan Jeon; In-Wook Choo
Journal:  Korean J Radiol       Date:  2005 Apr-Jun       Impact factor: 3.500

Review 3.  Successful thrombolytic therapy for acute kidney injury secondary to thrombosis of suprarenal inferior vena cava filter.

Authors:  Azra Bihorac; Craig S Kitchens
Journal:  J Thromb Thrombolysis       Date:  2009-11       Impact factor: 2.300

Review 4.  Venous thromboembolism in cancer patients: an underestimated major health problem.

Authors:  Jihane Khalil; Badr Bensaid; Hanan Elkacemi; Mohamed Afif; Younes Bensaid; Tayeb Kebdani; Noureddine Benjaafar
Journal:  World J Surg Oncol       Date:  2015-06-20       Impact factor: 2.754

5.  Outcome of anticoagulation with rivaroxaban in patients with non-retrieved inferior vena cava filters for the prevention of filter thrombosis: a retrospective cohort study.

Authors:  Baoyan Wang; Chenxiao Jiang; Yepeng Zhang; Xiaoqiang Li; Hang Xu
Journal:  BMC Cardiovasc Disord       Date:  2022-09-11       Impact factor: 2.174

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.